Sun Jie, Xi Hui-Yu, Shao Qing, Liu Qing-Huai
Department of Ophthalmology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
Department of Ophthalmology, Xuzhou First People's Hospital of Xuzhou Medical University, Xuzhou Eye Research Institute, Xuzhou 221002, Jiangsu Province, China.
Int J Ophthalmol. 2020 Feb 18;13(2):325-341. doi: 10.18240/ijo.2020.02.18. eCollection 2020.
Retinoblastoma (RB) is the most common intraocular malignancy of childhood caused by inactivation of the genes. The prognosis of RB is better with an earlier diagnosis. Many diagnostic approaches and appropriate clinical treatments have been developed to improve clinical outcomes. However, limitations exist when utilizing current methods. Recently, many studies have identified identify new RB biomarkers which can be used in diagnosis, as prognostic indicators and may contribute to understanding the pathogenesis of RB and help determine specific treatment strategies. This review focuses on recent advances in the discovery of RB biomarkers and discusses their clinical utility and challenges from areas such as epigenetics, proteomics and radiogenomics.
视网膜母细胞瘤(RB)是儿童期最常见的眼内恶性肿瘤,由基因失活引起。RB的预后随早期诊断而改善。已经开发了许多诊断方法和适当的临床治疗方法来改善临床结果。然而,在使用当前方法时存在局限性。最近,许多研究已经鉴定出可用于诊断、作为预后指标的新RB生物标志物,这些生物标志物可能有助于理解RB的发病机制并有助于确定具体的治疗策略。本综述重点关注RB生物标志物发现的最新进展,并从表观遗传学、蛋白质组学和放射基因组学等领域讨论它们的临床应用和挑战。